Skip to content
10-Q

Quarterly Report

REGENXBIO Inc. RGNX

0001193125-26-222804

← back to feed
Filed
May 14, 2026 12:00 AM ET
Period of report

On SEC.gov

Financials in this filing

Metric Period Value
Shares Outstanding Q1 2026 · May 8, 2026 51.7M sh
Shares Diluted Q1 2026 · Mar 31, 2026 52.43M sh
Shares Diluted Q1 2026 · Mar 31, 2025 51.43M sh
Capex Q1 2026 · Mar 31, 2026 $1.24M
Capex Q1 2026 · Mar 31, 2025 $1.02M
Operating Cash Flow Q1 2026 · Mar 31, 2026 −$76.19M
Operating Cash Flow Q1 2026 · Mar 31, 2025 $33.63M
Cash And Equivalents Q1 2026 · Mar 31, 2026 $15.23M
Cash And Equivalents Q1 2026 · Dec 31, 2025 $34.47M
Cash And Equivalents Q1 2026 · Mar 31, 2025 $130.1M
Stockholders Equity Q1 2026 · Mar 31, 2026 $21.08M
Stockholders Equity Q1 2026 · Dec 31, 2025 $102.73M
Stockholders Equity Q1 2026 · Mar 31, 2025 $274.2M
Stockholders Equity Q1 2026 · Dec 31, 2024 $259.65M
Current Liabilities Q1 2026 · Mar 31, 2026 $71.11M
Current Liabilities Q1 2026 · Dec 31, 2025 $118.1M
Total Liabilities Q1 2026 · Mar 31, 2026 $320.81M
Total Liabilities Q1 2026 · Dec 31, 2025 $350.3M
Current Assets Q1 2026 · Mar 31, 2026 $186.52M
Current Assets Q1 2026 · Dec 31, 2025 $281.28M
Total Assets Q1 2026 · Mar 31, 2026 $341.89M
Total Assets Q1 2026 · Dec 31, 2025 $453.03M
Eps Diluted Q1 2026 · Mar 31, 2026 −$1.72
Eps Diluted Q1 2026 · Mar 31, 2025 $0.12
Eps Basic Q1 2026 · Mar 31, 2026 −$1.72
Eps Basic Q1 2026 · Mar 31, 2025 $0.12
Sga Expense Q1 2026 · Mar 31, 2026 $21.31M
Sga Expense Q1 2026 · Mar 31, 2025 $20.35M
Rd Expense Q1 2026 · Mar 31, 2026 $57.34M
Rd Expense Q1 2026 · Mar 31, 2025 $53.09M
Net Income Q1 2026 · Mar 31, 2026 −$90.05M
Net Income Q1 2026 · Mar 31, 2025 $6.08M
Operating Income Q1 2026 · Mar 31, 2026 −$83.36M
Operating Income Q1 2026 · Mar 31, 2025 $12.13M
Revenue Q1 2026 · Mar 31, 2026 $6.39M
Revenue Q1 2026 · Mar 31, 2025 $89.01M